# Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)

> **NCT00102804** · PHASE3 · COMPLETED · sponsor: **Eli Lilly and Company** · enrollment: 663 (actual)

## Conditions studied

- Non-Small Cell Lung Cancer

## Interventions

- **DRUG:** Pemetrexed
- **DRUG:** Placebo
- **OTHER:** Best Supportive Care

## Key facts

- **NCT ID:** NCT00102804
- **Lead sponsor:** Eli Lilly and Company
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2005-03
- **Primary completion:** 2007-08
- **Final completion:** 2013-12
- **Target enrollment:** 663 (ACTUAL)
- **Last updated:** 2014-12-29


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00102804

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00102804, "Pemetrexed and Best Supportive Care Versus Placebo and Best Supportive Care in Non-Small Cell Lung Cancer (NSCLC)". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00102804. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*